JanOne Scientific Advisory Board Chair And Leading Pain Expert Featured on ABC-7 WJLA America This WeekPR Newswire PR Newswire • January 23, 2020
Dr. Christopher Kevil, pioneer in nitrite based PAD treatment and Dr. Amol Soin, foremost expert is neuropathic pain, provide scientific insight on the pain relieving qualities of JanOne’s lead drug candidate
Interview to be distributed nationally on all 193 Sinclair broadcasting network affiliate stations in 89 markets across the nation.
Las Vegas, Nevada, January 23, 2020 – JanOne Inc. (NASDAQ:JAN) Scientific Advisory Board Chair, Dr. Christopher Kevil sat down with Eric Bolling, JanOne’s President and Chairman and host of America This Week, to discuss the effects of the company’s lead drug candidate, TV1001SR, for the treatment of peripheral artery disease (PAD) and associated pain. Dr. Kevil was joined by renowned pain expert, Dr. Amol Soin, and both provided their insights and perspective for an approach that treats the mechanisms of a disease process, such as in PAD, and concurrently can have significant pain relieving qualities. Of particular interest was how in prior studies TV1001SR was able to treat both the underlying condition and the associated pain with no addictive repercussions. The company believes that this could mitigate the need for prescription opioids that often come with a risk for addiction, when patients are suffering from severe pain.
“We are excited about the prospects to successfully treat cardiovascular conditions but also the potential for treating other conditions that cause severe pain. Initial studies surpassed expectations for its potential with PAD and for other conditions such as diabetic neuropathy and wound healing. This was a result of some patients who saw increased blood flow and the repair of damaged nerves,” said Dr. Kevil, JanOne’s scientific advisory board chair. “We are looking forward to the advancement of these treatments in the coming year, especially if this ultimately replaces the need for addictive prescription opioids to treat disease associated pain.”
The full interview with Drs. Kevil and Soin can be seen on the KVLA website at the end of the America this week episode that aired on January 22, 2020.
JanOne is a unique NASDAQ-listed company that is focused on bringing medications to market to treat diseases that cause severe pain in an effort to reduce the need for prescriptions opioids often used to treat disease associated pain. The company is also exploring solutions for non-addictive pain medications. The lead candidate is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans, with plans currently underway for phase 2b trials. JanOne is currently dedicated to funding resources toward innovation, technology, and education for PAD and neuropathic pain. The company continues to operate its legacy businesses as subsidiaries, Appliance Recycling Centers of America and GeoTraq under their current brand names. Appliance Recycling Centers of America provides turnkey recycling and replacement services for utilities and other sponsors of energy efficiency programs. JanOne’s subsidiary GeoTraq engages in the development, design and sale of Mobile IoT modules. Please visit www.janone.com for additional information.
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the fact that TV1001SR could mitigate the need for prescription opioids, and other statements including words such as “continue”, “expect”, “intend”, “will”, “hope” “should”, “would”, “may”, “potential” and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant business, economic, competitive, political and social uncertainties, and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”).
Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in our filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.